• Minimum-to-Zero Cost

    Get early access to advanced non-invasive cancer treatment with little-to-no-cost from highly reputable hospitals and experts.

  • Access to New Therapies

    Explore new possibilities beyond standard treatment. Receive emerging therapies using technologies not yet widely available.

  • Care From Specialist Teams

    Be monitored closely by oncologists, research nurses, and cancer experts from highly reputable hospitals and universities.

Access Clinical Trials from Highly Reputable Hospitals & Institutions in Hong Kong

  • 100+

    Active cancer-related clinical trials across Hong Kong

  • 10+

    Major hospitals and research centers leading non-invasive treatment innovations, including histotripsy

  • 3000+

    Patients across the world supported every year through trial programs

Understanding Clinical Trial Phases

Phase I

Early Safety Trials

For patients who have exhausted standard treatments or need alternative options. This phase tests cutting-edge treatments in humans for the first time.

  • Focus: Safety & safe dosage
  • What to expect: Early access, more unknowns
  • Risk level: Highest uncertainty
  • Group size: Small (often under 100 people)

Phase II

Effectiveness Trials

For patients with the specific condition, the treatment targets. This phase looks at whether the treatment starts to work while continuing safety checks.

  • Focus: Does it work & at what dose
  • What to expect: Early signs of benefit
  • Risk level: Moderate uncertainty
  • Group size: Hundreds of patients

Phase III

Comparison & Confirmation Trials

For patients eligible for advanced, late-stage studies. This phase compares the new treatment with standard care or placebo.

  • Focus: Effectiveness vs. existing treatments
  • What to expect: Strong clinical evidence
  • Risk level: Lower uncertainty
  • Group size: Thousands of patients

Phase IV

Real World Follow-Up Studies

For patients already prescribed the approved treatment. This phase tracks long-term safety and real-world outcomes.

  • Focus: Long-term effects & quality of life
  • What to expect: Ongoing monitoring
  • Risk level: Lowest uncertainty
  • Group size: Tens of thousands

How We Ensure Your Safety During Clinical Trials

  • Strict selection and ethical approval

    Only trials from reputable hospitals are listed, and each must pass independent ethics review and meet international GCP standards.

    1
  • Highly secure eligibility check

    Complete a secure pre-eligibility check in Medichoice to confirm suitability. Your health data stays private at all times.

    2
  • Informed consent

    Clear explanations of the study, risks, and requirements are provided before you choose to join.

    3
  • Communication support

    Medichoice helps coordinate communication between patients and research institutions for smooth updates and guidance.

    4
  • Continuous monitoring by oncology teams

    During the trial, cancer specialists from reputable hospitals monitor your health and treatment response

    5
  • Option to withdraw anytime

    You may leave the trial whenever you choose, without affecting your regular care. You can also request data deletion from our system.

    6
  • Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma

    • Phase: II
    • Liver-cancer (Hepatocellular Carcinoma)
    • Chinese University of Hong Kong (CUHK)
  • Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

    • Phase: II
    • Liver-cancer (Hepatocellular Carcinoma)
    • The University of Hong Kong (HKU)
  • Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

    • Phase: III
    • Liver-cancer (Hepatocellular Carcinoma), advanced stage
    • Humanity & Health Medical Group Limited
  • TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

    • Phase: II
    • Liver-cancer (Hepatocellular Carcinoma)
    • Queen Mary Hospital, The University of Hong Kong
1 of 4